Molecularly Aided Stratification for Tumor Eradication Research

Recruiting

• Conditions: Rare Cancers; Multiomics

• Registration Number: NCT05852522
• Lead Sponsor: German Cancer Research Center

Brief Summary

NCT/DKFZ/DKTK MASTER is a prospective, continuously recruiting, multicenter observational study for biology-guided stratification of adults with rare cancers, including rare subtypes of common entities, using comprehensive molecular profiling, and clinical decision-making in a multidisciplinary molecular tumor board.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-11-11
• Study First Submitted: 2023-04-24
• Study First Submitted QC: 2023-05-02
• Study First Posted: 2023-05-10
• Status Verified: 2024-06
• Last Update Submitted: 2025-02-28
• Last Update Posted: 2025-03-04
• Primary Completion: 2028-10
• Study Completion: 2029-10

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 10000

Inclusion Criteria

Rare cancer (Incidence <6/100,000 persons/year) or Rare subtype of a more common entity (case-by-case decision; example: pancreatic ductal adenocarcinoma without KRAS mutation)

Metastatic and/or locally advanced cancer with no curative therapy option and indication for systemic therapy

Exclusion Criteria

Severe neurological or psychiatric disorder interfering with the ability to give oral and written informed consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
overall survival	10 years	time period of survival from date of diagnosis
progression free survival	5 years	Time period of progression survival from date of multiomics analysis

Secondary Outcome Measures

Name	Time	Method
response to antitumor treatment	5 months	response according to RECIST v.1.1 criteria to antitumor treatment applied after multiomics analysis

Trial Locations

Locations (1)

German Cancer Research Center; 🇩🇪 Heidelberg, Germany